Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials.

about

Hemophilia Care in the Pediatric Age.Nonacog Beta Pegol: A Review in Haemophilia B.GlycoPEGylated recombinant factor IX for hemophilia B in context Practical aspects of extended half-life products for the treatment of haemophilia

P2860

Q33737259-13B2E234-D3DE-4DA6-8931-1681DBAFB66E Q45874270-A18AE03F-A12F-47B2-ABC1-16B7B201A9F0 Q57158345-3E1137DD-D5A5-49BE-8943-CD0976CC46B0 Q58761664-F952716A-A9DB-47A4-B734-FB3B5EAF0193

P2860

Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials.

Item

http://www.wikidata.org/entity/Q38944641

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Pharmacokinetics of a novel ex ...... m two phase 3 clinical trials.

@en

type

Item

label

Pharmacokinetics of a novel ex ...... m two phase 3 clinical trials.

@en

prefLabel

Pharmacokinetics of a novel ex ...... m two phase 3 clinical trials.

@en

P1476

Pharmacokinetics of a novel ex ...... om two phase 3 clinical trials

@en

P2093

E Santagostino

http://www.w3.org/2001/XMLSchema#string

F Abdul-Karim

http://www.w3.org/2001/XMLSchema#string

G Young

http://www.w3.org/2001/XMLSchema#string

J Oldenburg

http://www.w3.org/2001/XMLSchema#string

P Persson

http://www.w3.org/2001/XMLSchema#string

S Kearney

http://www.w3.org/2001/XMLSchema#string

T Matsushita

http://www.w3.org/2001/XMLSchema#string

W H O Clausen

http://www.w3.org/2001/XMLSchema#string

P2860

Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels.

BAX326 (RIXUBIS): a novel recombinant factor IX for the control and prevention of bleeding episodes in adults and children with hemophilia B

Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial

Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective.

Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia.

Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide.

WFH: closing the global gap--achieving optimal care.

Recombinant long-acting glycoPEGylated factor IX (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials.

Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm™4).

Clinical severity of haemophilia A: does the classification of the 1950s still stand?

P304

547-555

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/HAE.13191

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

A Tiede

C Negrier

M Carcao

P577

2017-02-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28233381

http://www.w3.org/2001/XMLSchema#string

P921

hemophilia

hemophilia B

Coagulation factor IX

phase III clinical trial

Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials.

about

P2860

P2860

Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921